Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2008-002060-34-AT
EUCTR2008-002060-34-AT
Active, not recruiting
Not Applicable

Impact of Inhibition of Thrombocyte Activation on the course of chronic Hepatitis C

Medizinische Universität Wien; Univ.Klin.f.Innere Med. III, Abt.f.Gastroenterologie u. Hepatologie0 sitesOctober 21, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsPlavix®Aspirin®Pletal®Pradaxa®

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Medizinische Universität Wien; Univ.Klin.f.Innere Med. III, Abt.f.Gastroenterologie u. Hepatologie
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 21, 2008
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Medizinische Universität Wien; Univ.Klin.f.Innere Med. III, Abt.f.Gastroenterologie u. Hepatologie

Eligibility Criteria

Inclusion Criteria

  • •\- confirmed chronic hepatitis C (IFN\-naive or non\-responders/relapsers to previous therapy)
  • •\-ALAT (GPT) \> 80 U/l for women, and \> 90 U/l for men. These values represent double the upper limit of the normal range of ALAT, which is different for males and females.
  • •\-Age: 19 years or older
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years)
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years)
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\-Cirrhosis: CHILD\-PUGH Stage B and C
  • •\-Impaired haemostasis (PTZ \< 50\)
  • •\-Impaired kidney function (Creatinine \> 1\.3mg/dl)
  • •\-Co\-infection with HBV or HIV
  • •\-Platelet count \< 50,000/µl
  • •\- History of variceal bleeding or evidence of GI blood loss
  • •\- History of thromboembolic or severe cardiovascular disease
  • •\-Hypertension not responding to anti\-hypertensive treatment
  • •\-History of convulsion
  • •\-Participation in a clinical trial in the 3 weeks preceding the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Potential influence of coagulation inhibitionon the perception of fear or aggressivenessI48Atrial fibrillation and flutter
DRKS00017043niversitätsklinik für Kardiologie und Angiologie25
Completed
Not Applicable
Impact of continued use of antithrombotic drugs on the risk of delayed post-polypectomy bleeding after endoscopic mucosal resection/endoscopic submucosal dissection for gastrointestinal lesions; prospective study
JPRN-UMIN000040449agaoka Red Cross Hospital283
Completed
Not Applicable
Impact of antithrombotic agent on the clinical course after pancreatectomyperioperative complication
JPRN-UMIN000027919ara Medical University1,000
Completed
Not Applicable
Effects of antithrombotic drugs on thrombosis and bleeding risk in patients undergoing thoracic surgerythrombosisbleedingBlood - Other blood disordersBlood - Clotting disorders
ACTRN12619001417178Ayten Saracoglu100
Active, not recruiting
Phase 1
The prevention of thrombosis in patients with pancreatic cancer using TinzapariThromboprophylaxis in patients with advanced pancreatic cancerMedDRA version: 20.0Level: PTClassification code 10043607Term: ThrombosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 21.1Level: PTClassification code 10068067Term: Tumour thrombosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-005530-42-GRInstitute of Molecular Medicine and Biomedical Research (IMBE)450